Completed PHASE1 INTERVENTIONAL 2-arm NCT06229548

A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SYH2053

A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SYH2053 in Subjects With Normal or Elevated Low-Density Lipoprotein Cholesterol

Sponsor: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

Conditions Hyperlipemia

Interventions Placebo SYH2053

Updated 4 times since 2024 Last updated: Apr 2, 2025 Started: Jan 8, 2024 Primary completion: Dec 23, 2024 Completion: Mar 25, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Hyperlipemia and is currently completed. CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. leads this study, which shows 4 recorded versions since 2024 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

4 versions recorded

May 2025 — Present [monthly]

Completed PHASE1

Status: Not Yet Recruiting → Completed
Sep 2024 — May 2025 [monthly]

Not Yet Recruiting PHASE1
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting PHASE1
Feb 2024 — Jul 2024 [monthly]

Not Yet Recruiting PHASE1

First recorded

Jan 2024

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

Data source: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China